Komplike Hipertiroidik Olguda Anestezi

Authors

Hatice Betül Altınışık
https://orcid.org/0000-0001-9273-0876

Synopsis

This case report discusses the anesthesia experience and postoperative complication management in a 21-year-old female patient with Basedow-Graves disease and factor-VII deficiency who underwent an emergency total thyroidectomy. Because euthyroidism could not be achieved despite medical therapy and metimazole-induced elevated liver enzymes, and due to worsening dyspnea, emergency surgery was planned under a beta-blocker (propranolol) cover per endocrinology consultation. Based on hematology recommendations, recombinant factor-VIIa (Novoseven RT) was administered preoperatively to manage bleeding risk. Thiopental and remifentanil were used for anesthesia induction, rocuronium as the muscle relaxant, and neuromuscular blockade was reversed with sugammadex at the end of surgery. In the early postoperative period, the patient developed bilateral upper extremity paralysis. Investigations including EMG, cervical MRI, Doppler US, and brain CT revealed no surgical nerve injury, position-related brachial plexus damage, or gross cerebral hemorrhage/embolism. Although not definitively proven, the condition was attributed to a microembolic cerebrovascular accident (CVA) associated with recombinant factor-VIIa administration. Following enoxaparin therapy and two weeks of physical rehabilitation, the patient's muscle strength completely returned to normal 20 days post-surgery, resulting in full recovery.

References

Doubleday AR, Sippel RS. Hyperthyroidism.Gland Surg. 2020 Feb;9(1):124-135.

Vidal López F. [Hyperthyroidism and anesthesia]. Rev Esp Anestesiol Reanim. 1974 Mar;21(2):97-111.

Temizel F, Doğu D, Çelik G, İtez S, Arıkan Z. Hipertiroidizm ve anestezi. Göztepe Tıp Dergisi 18: 177-178, 2003

Leporati P, Groppelli G, Zerbini F, et al. Etiopathogenesis of Basedow's disease. Trends and current aspects. Nuklearmedizin. 2015;54(5):204-10.

Klenczar K, Deja G, Kalina-Faska B, et al. [Myasthenia gravis, Graves-Basedow disease and other autoimmune diseases in patient with diabetes type 1 - APS-3 case report, therapeutic complications]. Pediatr Endocrinol Diabetes Metab. 2017;23(3):159-164.

Tatulashvili S, Baudry C, Sadoul JL, et al. [New perspectives for the diagnosis and prognosis of Graves' disease]. Ann Endocrinol (Paris). 2018 Sep;79 Suppl 1:S31-S39.

Sevenet PO, Kaczor DA, Depasse F. Factor VII Deficiency: From Basics to Clinical Laboratory Diagnosis and Patient Management. Clin Appl Thromb Hemost. 2017 Oct;23(7):703-710.

Piantanida E. Preoperative management in patients with Graves' disease. Gland Surg. 2017 Oct;6(5):476-481.

Yamashita S, Amino N, Shong YK. The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea. Thyroid. 2011 Jun; 21(6):577-80.

Burch HB, Burman KD, Cooper DS. A. 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab 2012;97:4549-58.

Ross DS, Burch HB, Cooper DS, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343-421.

Klubo-Gwiezdzinska J, Wartofsky L. Thyroid emergencies. Med Clin North Am. 2012 Mar; 96(2):385-403.

De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016 Aug 27; 388(10047):906-918.

Sabljak V, Kalezić N, Ivanović B, et al. Modern concepts of preoperative preparation of patients with thyroid gland disease. Acta Chir Iugosl. 2011;58(2):103-8.

Bartalena L, Burch HB, Burman KD, et al. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol (Oxf). 2016 Jan; 84(1):115-20.

Tsatsoulis A, Johnson EO, Kalogera CH, et al. The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol 2000;142:231-5.

Sebastian-Ochoa A, Quesada-Charneco MA, Reyes-Garcia R, et al. Dramatic response to cholestyramine in a patient with Graves'disease resistant to conventional therapy. Thyroid 2008;18:1115-7.

Yang Y, Hwang S, Kim M, et al. Refractory Graves'disease successfully cured by adjunctive cholestyramine and subsequent total thyroidectomy. Endocrinol Metab (Seoul) 2015;30:620-5.

Palace MR. Perioperative Management of Thyroid Dysfunction. Health Serv Insights. 2017 Feb 20;10:1178632916689677.

Kohl BA, Schwartz S. Surgery in the patient with endocrine dysfunction. Med Clin North Am. 2009;93:1031–1047.

Sawin CT, Geller A, Wolf P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–1252.

Auer J, Scheibner P, Mische T, et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142:838–842.

Sukhminder Jit Singh Bajwa, Gurpreet Kaur. Endocrinopathies: The current and changing perspectives in anesthesia practice. Indian J Endocrinol Metab. 2015 Jul-Aug; 19(4): 462–469.

Stehling LC. Anesthetic management of the patient with hyperthyroidism. Anesthesiology. 1974 Dec;41(6):585-95.

Hirvonen EA, Niskanen LK, Niskanen MM. Thyroid storm prior to induction of anaesthesia. Anaesthesia. 2004;59(10):1020–1022.

Temel Anestezi, Yüksek Keçik, Güneş Tıp Kitabevleri, 2016, 2. Baskı Sy:619-630

Türkmen ÜA, Kara D, Köksal Ç. Tiroid Bezi Hastalıklarında Anestezik Yaklaşım. Okmeydanı Tıp Dergisi 28(Ek sayı 1):48-55, 2012.

Bacuzzi A, Dionigi G, Del Bosco A, et al. Anaesthesia for thyroid surgery: Perioperative management. Int J Surg 2008;6:S82-S5.

Dogan E, Akdemir MS, Guzel A, et al. A miracle that accelerates operating room functionality: sugammadex. Biomed Res Int. 2014;2014:945310. doi: 10.1155/2014/945310.

Acar S, Ercetin C, Sahbaz NA, et al. Hemodynamic Instability during Thyroidectomy in Graves' Disease. J Invest Surg. 2021 Apr 28:1-5.

Short HL, Tamatea J, Conaglen HM, et al. The safety of anaesthetising biochemically hyperthyroid patients undergoing thyroidectomy-a retrospective cohort study. Anaesth Intensive Care. 2018 Jul;46(4):396-399.

Erbil Y, Ozluk Y, Giris M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves'disease. J Clin Endocrinol Metab 2007;92:2182-9.

Porterfield JR Jr, Thompson GB, Farley DR, et al. Evidence-based management of toxic multinodular goiter (Plummer's Disease). World J Surg. 2008 Jul; 32(7):1278-84.

Gualniera P, Scurria S, Mondello C, et al. Narrative review of proving the causal link of recurrent laryngeal nerve injury and thyroidectomy: a medico legal appraisal. Gland Surg. 2020 Oct;9(5):1564-1572.

Luginbuhl A, Schwartz DM, Sestokas AK, et al. Detection of evolving injury to the brachial plexus during transaxillary robotic thyroidectomy. Laryngoscope. 2012 Jan;122(1):110-5.

Klinik Anestezi Temelleri, P.G. Barash, Lippincott WW, (Türkçe Çevirisi, Karamehmet Yıldız), Güneş Tıp Kitabevleri, 2017 Sy:418

Kang SW, Lee SC, Lee SH, et al. Robotic thyroid surgery using a gasless transaxillary approach and the da Vinci S system: the operative outcomes of 338 consecutive patients. Surgery 2009; 146: 1048–1055.

Robinson MT, Rabinstein AA, Meschia JF, et al. Safety of recombinant activated factor VII in patients with warfarin-associated hemorrhages of the central nervous system. Stroke. 2010 Jul;41(7):1459-63.

Schmid P, Mordasini A, Luginbühl M, et al. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients. Swiss Med Wkly. 2011 Jul 7;141:w13213. doi: 10.4414/smw.2011.13213.

Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose Factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542–7.

O’Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293–8.

Published

January 13, 2022

License

License